Relief as Apex Indian court seeks details on trial safeguards
This article was originally published in Scrip
In what perhaps will come as a significant relief for industry, the Supreme Court order in a case concerning clinical trials in India appears less harsh than originally made out to be, with the apex court only seeking certain details on how the current regime safeguards trial participants with reference to the clearances granted for 162 proposals by the Drugs Controller General of India (DCGI).
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.